There is a wider opportunity for BESREMi; Jakafi is not a direct competitor to Besremi, and there is uncertainty around Rusfertide’s uptake. BESREMi is expanding its horizon in the first-line treatment of Polycythemia vera; JAKAFI’s impressive growth in second-line treatment
The polycythemia vera treatment paradigm for patients has shifted significantly in the last few years. Previously, the polycythemia vera treatment landscape was dominated by generic medicines such as aspirin, hydroxyurea, interferons, and phlebotomy until the approval of JAKAFI in the US in 2014, a JAK inhibitor developed by Incyte as a second-line treatment for polycythemia vera patients. An...